Small Cell Lung Cancer

SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more effective treatments.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional therapy.

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which authors say minimizes the need for supportive care.

Small cell lung cancer (SCLC) is strongly linked to smoking, with about 80% of lung cancer deaths attributed to tobacco use.

Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Bellinda King-Kallimanis, PhD, LUNGevity Foundation, reflects on her experiences in patient-focused research to discuss the current state of patient education, the importance of patient advocates, and mediating barriers to health care access.

The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer. Sandip Patel, MD, joined for an interview looking forward to the unique features of this year's meeting.

A high number of adverse events were reported in a late-stage trial conducted by Merck for treatment in lung cancer.

This editorial describes the need for a system that helps primary care physicians prioritize shared decision-making for preventive services.

The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).

Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.

The treatment developed by Amgen could be the first therapeutic option approved for third-line treatment of advanced small cell lung cancer (SCLC).

Improved psychological distress and physical function were among the benefits of doing aerobic exercise and tai chi as a patient with lung cancer.

A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.

Early CT screening leads to a 20-year lung cancer survival rate of 81%.

Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.

Up to 30 million individuals could lose Medicaid coverage; a new initiative demands increased focus on women's health issues; survey reports increased 5-year lung cancer survival rates from 2015 to 2019.

The American Cancer Society expanded eligibility for lung cancer screening; experts advised patients to do their research before choosing a plan from the Affordable Care Act’s insurance marketplaces; Republican-led states partnering with rideshare companies for medical appointment rides.

Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.

School nurses play an overworked and understaffed role; Merck's immunotherapy Keytruda (pembroilzumab) has been granted approval for pre- and postsurgical treatment in lung cancer; the FDA is helping to curb tobacco-related health disparities.

Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.

Following discussions with FDA, Takeda will voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) based on the outcomes of the phase 3 EXCLAIM-2 trial.

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.

Women have a higher likelihood of having hormone receptor (HR+) non-small cell lung cancer (NSCLC) than men, and mutations of EGFR and KRAS were more common in HR+ NSCLC in a recent study.

Osimertinib administered in addition to chemotherapy showed more progression-free survival (PFS) benefit than just osimertinib in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC).

Patients with advanced or metastatic non–small cell lung cancer (NSCLC) were able to specify a 1-point threshold when describing meaningful symptom change, for better or worse, that helped illustrate their symptom experience.